Tessa Romero
Stock Analyst at J.P. Morgan
(4.64)
# 895
Out of 4,696 analysts
202
Total ratings
54.8%
Success rate
19.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintained: Buy | n/a | $71.93 | - | 34 | Aug 20, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Buy | $53 → $60 | $41.98 | +42.93% | 22 | Aug 20, 2026 | |
| SEPN Septerna | Maintained: Buy | $38 → $48 | $37.50 | +28.00% | 4 | Aug 19, 2026 | |
| EYPT EyePoint | Downgraded: Hold | n/a | $4.79 | - | 8 | Aug 17, 2026 | |
| OCS Oculis Holding AG | Rated: Buy | $23 → $20 | $12.02 | +66.39% | 5 | Aug 14, 2026 | |
| UPB Upstream Bio | Maintained: Hold | $8 → $9 | $6.48 | +38.89% | 11 | Aug 14, 2026 | |
| SRRK Scholar Rock Holding | Rated: Buy | $56 → $63 | $56.10 | +12.30% | 10 | Aug 13, 2026 | |
| XENE Xenon Pharmaceuticals | Maintained: Buy | $82 | $60.16 | +36.30% | 16 | Aug 11, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Hold | n/a | $25.14 | - | 14 | Jul 30, 2026 | |
| BHVN Biohaven | Maintained: Buy | n/a | $15.69 | - | 14 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.87 | +132.56% | 2 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.78 | +88.28% | 4 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $31 | $34.13 | -9.17% | 17 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $25.82 | - | 3 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $24.88 | +68.81% | 2 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.38 | - | 5 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $3.86 | - | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $34 | $28.93 | +17.53% | 19 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.67 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.54 | n/a | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.89 | n/a | 4 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $10 | $9.44 | n/a | 2 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $49.42 | n/a | 1 | Nov 9, 2020 |
Cytokinetics
Aug 20, 2026
Maintained: Buy
Price Target: n/a
Current: $71.93
Upside: -
Edgewise Therapeutics
Aug 20, 2026
Rated: Buy
Price Target: $53 → $60
Current: $41.98
Upside: +42.93%
Septerna
Aug 19, 2026
Maintained: Buy
Price Target: $38 → $48
Current: $37.50
Upside: +28.00%
EyePoint
Aug 17, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.79
Upside: -
Oculis Holding AG
Aug 14, 2026
Rated: Buy
Price Target: $23 → $20
Current: $12.02
Upside: +66.39%
Upstream Bio
Aug 14, 2026
Maintained: Hold
Price Target: $8 → $9
Current: $6.48
Upside: +38.89%
Scholar Rock Holding
Aug 13, 2026
Rated: Buy
Price Target: $56 → $63
Current: $56.10
Upside: +12.30%
Xenon Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $82
Current: $60.16
Upside: +36.30%
Dyne Therapeutics
Jul 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $25.14
Upside: -
Biohaven
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $15.69
Upside: -
Jun 29, 2026
Reiterated: Buy
Price Target: $9
Current: $3.87
Upside: +132.56%
Jun 25, 2026
Maintained: Buy
Price Target: $9
Current: $4.78
Upside: +88.28%
Jun 11, 2026
Rated: Hold
Price Target: $31
Current: $34.13
Upside: -9.17%
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $25.82
Upside: -
Jun 8, 2026
Reiterated: Buy
Price Target: $42
Current: $24.88
Upside: +68.81%
May 26, 2026
Maintained: Sell
Price Target: n/a
Current: $1.38
Upside: -
Apr 2, 2026
Maintained: Sell
Price Target: n/a
Current: $3.86
Upside: -
Mar 4, 2026
Rated: Buy
Price Target: $31 → $34
Current: $28.93
Upside: +17.53%
Nov 18, 2025
Maintained: Hold
Price Target: n/a
Current: $3.67
Upside: -
Oct 23, 2024
Downgraded: Sell
Price Target: n/a
Current: $5.54
Upside: n/a
Oct 18, 2024
Maintained: Hold
Price Target: n/a
Current: $3.89
Upside: n/a
Jul 13, 2022
Downgraded: Hold
Price Target: $22 → $10
Current: $9.44
Upside: n/a
Nov 9, 2020
Downgraded: Hold
Price Target: n/a
Current: $49.42
Upside: n/a